Improving HIV treatment for children and adolescents using Dolutegravir
Official title: Addressing Research Gaps to Optimize Dolutegravir-based ART in Children and Adolescents
Funded at University of Florida · NIH-11007541 · Data updated 2026-11-12
This study is looking to make HIV treatment better for kids and teens by figuring out the best doses and safety of a medicine called Dolutegravir, especially for those living in low- and middle-income countries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | August 5, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $690,567 |
| NIH project number | 1R01AI186847-01 |
| Project ID | NIH-11007541 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and adolescents aged 0 to 21 years who are living with HIV and are currently receiving or are eligible for antiretroviral therapy.
✕Less likely to help
Patients who are not living with HIV or those who are older than 21 years may not receive any benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of Dolutegravir-based antiretroviral therapy (ART) for children and adolescents living with HIV. It aims to address existing gaps in knowledge regarding the appropriate dosing and safety of Dolutegravir in younger populations, particularly in low- and middle-income countries. By investigating the unique needs of children and adolescents, the study seeks to optimize treatment regimens that are more tolerable and effective, ultimately improving health outcomes. The research will involve collecting data on drug interactions and the impact of weight-based dosing in pediatric patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better health outcomes for children and adolescents living with HIV.
How similar studies have gone: Previous research has shown promising results with Dolutegravir in adult populations, but this specific approach in pediatric settings is still being explored.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Kwara, Awewura Jacob — University of Florida
- Study coordinator: Kwara, Awewura Jacob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.